NCT04641078 2024-02-28
DART
University Hospital, Ghent
Phase 2 Unknown
Clinical Trials
227 trialsNCT04492293 2024-02-26
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2 Unknown
NCT06251492 2024-02-20
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Fudan University
Phase 2 Unknown
NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT03899077 2024-02-07
SAVE
Cancer Research Antwerp
Phase 2 Unknown
NCT04419402 2024-02-07
ENZA-p
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT05567588 2024-02-01
Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT06222125 2024-01-24
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
Huabo Biopharm Co., Ltd.
Phase 2 Unknown
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
NCT06129955 2023-11-13
Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05555017 2023-10-06
Trace-II
The Netherlands Cancer Institute
Phase 2 Unknown
NCT05975151 2023-09-21
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Qilu Hospital of Shandong University
Phase 2 Unknown
NCT05979740 2023-08-31
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
RenJi Hospital
Phase 2 Unknown
NCT05578664 2023-08-30
PE-PE
Consorzio Oncotech
Phase 2 Unknown
NCT06009848 2023-08-24
Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03961698 2023-08-14
MARIO-3
Infinity Pharmaceuticals, Inc.
Phase 2 Unknown
NCT05986981 2023-08-14
MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05900973 2023-08-07
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
D'Or Institute for Research and Education
Phase 2 Unknown
NCT05879471 2023-07-24
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05955209 2023-07-21
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT05879497 2023-07-13
68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05879510 2023-07-13
68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03940235 2023-06-28
RADIOSA
European Institute of Oncology
Phase 2 Unknown
NCT05902377 2023-06-15
68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05823246 2023-05-26
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05877911 2023-05-26
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT03774901 2023-04-21
PULSE
Centre Hospitalier Universitaire de Besancon
Phase 2 Unknown
NCT00951535 2023-04-06
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Unknown
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04543110 2023-03-23
RADIANT
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05717660 2023-02-08
PERSIAN
Azienda Ospedaliero-Universitaria Careggi
Phase 2 Unknown
NCT05249712 2023-01-03
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04869371 2022-12-29
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05445648 2022-12-28
CBPTMI
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05667636 2022-12-28
esSBRT
Regina Elena Cancer Institute
Phase 2 Unknown
NCT04356430 2022-12-16
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04730219 2022-11-30
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT02613819 2022-11-18
FASTRACK II
Trans Tasman Radiation Oncology Group
Phase 2 Unknown
NCT05167175 2022-10-25
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05461261 2022-10-24
The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT03529890 2022-10-20
RACE IT
Technical University of Munich
Phase 2 Unknown
NCT05564897 2022-10-04
Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05038657 2022-10-03
AURORA
University Hospital Southampton NHS Foundation Trust
Phase 2 Unknown
NCT04913025 2022-09-21
REFINE
University College, London
Phase 2 Unknown
NCT05401279 2022-08-18
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
RenJi Hospital
Phase 2 Unknown
NCT05440045 2022-08-17
A Clinical Study of 6MW3211 in Patients With Renal Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Unknown
NCT05285319 2022-08-10
Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer
Cairo University
Phase 2 Unknown